Intraocular Pharmacokinetics of Erythropoietin After Single Intravitreal Injection in Human

2014-07-24 14:01:12 | BioPortfolio


The investigators investigate intraocular concentrations and pharmacokinetics of erythropoietin after a single intravitreal injection in humans.


Intravitreal injections of erythropoietin for off-label use have been shown to be beneficial in eyes with diabetic macular edema.However, the pharmacokinetic profile of erythropoietin after intravitreal injection in humans has not yet been determined clearly. The purpose of this study was to determine the intraocular pharmacokinetics of erythropoietin after a single intravitreal injection in a prospective investigation.

Study Design

Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment






Hallym University Sacred Heart Hoapital
Korea, Republic of




Hallym University Medical Center

Results (where available)

View Results


Published on BioPortfolio: 2014-07-24T14:01:12-0400

Clinical Trials [246 Associated Clinical Trials listed on BioPortfolio]

Postoperative Evolution After Small Gauge Vitrectomy Without Eye Occlusion

After an uneventfully small gauge vitrectomy we don´t think is necessary to occlude the eye for 24 hours

Choroidal Thickness Vitrectomy

The purpose of this study is to assess the influence of vitrectomy on changes in central choroidea and comparing the results in imaging of the choroidea with two different OCT devices. ...

Evaluation of Vitrectomy for Diabetic Macular Edema

The study is designed as a prospective cohort study to assess changes in visual acuity and retinal thickening and surgical complications in subjects undergoing vitrectomy for diabetic macu...

PK Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Undergoing Vitrectomy

The purpose of this study is to evaluate the pharmacokinetics (PK) of dexamethasone phosphate ophthalmic solution delivered via the EyeGate® II Drug Delivery System (EGDS) in patients und...

Perfluorocarbon Perfused Vitrectomy and 3D Vitrectomy System in Advanced Diabetic Retinopathy

To investigate the feasibility and advantages of using perfluorocarbon liquid (PCL) perfusion to remove vitreous during suction-cutting vitrectomy using a dual, dynamic drive (3D)technolog...

PubMed Articles [801 Associated PubMed Articles listed on BioPortfolio]

Importance of vitrectomy in endophthalmitis : How immediate vitrectomy can restore visual acuity.

This article presents a case of endophthalmitis after intravitreal injection with bevacizumab (Avastin®) in a patient suffering from exudative age-related macular degeneration (AMD). Within 1h afte...

ULTRASOUND IN VITRECTOMY: An Alternative Approach to Traditional Vitrectomy Techniques.

To study a prototype of an ultrasound-based vitrector, and to try to understand the physical phenomena underlying this new technology.

Soloist performance of vitrectomy probe in proliferative diabetic retinopathy.

To evaluate the feasibility and outcomes of the sole use of 23g pars plana vitrectomy in cases with diabetic vitreous hemorrhage with vitreoretinal traction.

Internal limiting membrane peeling versus no peeling during primary vitrectomy for rhegmatogenous retinal detachment: A systematic review and meta-analysis.

Internal limiting membrane (ILM) peeling during primary vitrectomy for rhegmatogenous retinal detachment (RRD) prevents the formation of postoperative macular epiretinal membrane (ERM). However, studi...

The rate of endophthalmitis after pars plana vitrectomy and its risk factors.

To study the incidence of endophthalmitis after pars plana vitrectomy, its causative organisms, and visual acuity outcomes.

Medical and Biotech [MESH] Definitions

Removal of the whole or part of the vitreous body in treating endophthalmitis, diabetic retinopathy, retinal detachment, intraocular foreign bodies, and some types of glaucoma.

Agents that aid or increase the action of the principle drug (DRUG SYNERGISM) or that affect the absorption, mechanism of action, metabolism, or excretion of the primary drug (PHARMACOKINETICS) in such a way as to enhance its effects.

Naturally occurring genetic variations associated with drug response (e.g., dosage, extent and rate of metabolic processes). While these variants are not markers for GENETIC PREDISPOSITION TO DISEASE they influence PHARMACOKINETICS and pharmacodynamics and often occur on genes encoding drug metabolism enzymes and transporters (e.g., ANGIOTENSIN CONVERTING ENZYME; CYTOCHROME P-450 CYP2D6).

More From BioPortfolio on "Intraocular Pharmacokinetics of Erythropoietin After Single Intravitreal Injection in Human"

Quick Search


Relevant Topics

Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

Searches Linking to this Trial